AI and data sharing essential for safer cell and gene therapies, says industry leader

The author argues that keeping data secret in cell and gene therapy harms patients, and that a commitment to transparency and artificial intelligence is needed to make these treatments safer and more effective.

He likens the current state of the field to early aviation, when airlines guarded information and only after a series of crashes did the industry adopt the "black box" concept to share data and rebuild public trust.

The piece calls on companies to move past the "pre‑black box" stage, embrace shared failure analysis, and use AI to learn from collective experience, suggesting this will accelerate the evolution of cell and gene therapies.